

“Cancer Care 2.0”

The team’s tumour mapping pipeline could inform decision-making across the whole patient journey.

1 Screening
simple, non-invasive tests to detect metabolic signatures, for example in urine and stool samples

2 Diagnostics
metabolic-signature detection of biopsies for real-time patient stratification

3 Surgical treatment
using the iKnife for surgical margin control and to match patients to treatment according to metabolic changes

4 Non-surgical therapy
identifying therapeutic targets and developing new drugs on the basis of metabolic weaknesses

5 Monitoring
a simple test that, in addition to screening, could enable monitoring of how a patient is responding to therapy or whether their cancer is likely to return after treatment